Skip to main content
padlock icon - secure page this page is secure

Pretargeted antibody-guided radioimmunotherapy in a child affected by resistant anaplastic large cell lymphoma

Buy Article:

$59.00 + tax (Refund Policy)

Abstract

Anaplastic large cell lymphoma (ALCL) is characterized by preferential paracortical and intrasinusoidal lymph node involvement by large anaplastic tumor cells expressing the CD30 antigen. Up to 80% of pediatric patients with ALCL can be cured with multi-agent chemotherapeutic regimens. Patients resistant to chemotherapy or suffering from early relapse have a poor prognosis and a poor chance of survival. In these cases, the highly aggressive clinical course of ALCL, associated with systemic symptoms and extranodal involvement, has been treated with different approaches in various cooperative trials, including conventional chemotherapy and human stem cell transplantation (HSCT). However, the optimal treatment has not yet been defined, in particular in cases of relapse.

More recently, radioimmunotherapy has been studied with encouraging results in cancer patients, including non-Hodgkin’s lymphoma.

Here we describe the case of a pediatric ALCL, relapsing after HSCT, treated with pretargeted antibody-guided radioimmunotherapy, obtaining a complete remission, with excellent quality of life over the past 10 months.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: anaplastic large cell lymphoma; pediatric non-Hodgkin’s lymphoma; radioimmunotherapy

Document Type: Research Article

Affiliations: 1: Department of Public Health and Cell Biology, Pediatrics, University of Rome “Tor Vergata” c/o Ospedale “S. Eugenio”, Rome 2: Nuclear Medicine Division, European Institute of Oncology, Milan 3: Sigma-Tau Industrie Farmaceutiche Riunite SpA, Pomezia, Rome, Italy

Publication date: September 1, 2007

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more